J
Jacqueline C. Barrientos
Researcher at Hofstra University
Publications - 167
Citations - 11652
Jacqueline C. Barrientos is an academic researcher from Hofstra University. The author has contributed to research in topics: Chronic lymphocytic leukemia & Ibrutinib. The author has an hindex of 33, co-authored 143 publications receiving 9545 citations. Previous affiliations of Jacqueline C. Barrientos include The Feinstein Institute for Medical Research & Howard Hughes Medical Institute.
Papers
More filters
Journal ArticleDOI
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
Richard R. Furman,Jeff P. Sharman,Steven Coutre,Bruce D. Cheson,John M. Pagel,Peter Hillmen,Jacqueline C. Barrientos,Andrew D. Zelenetz,Thomas J. Kipps,Ian W. Flinn,Paolo Ghia,Herbert Eradat,Thomas J. Ervin,Nicole Lamanna,Bertrand Coiffier,Andrew R. Pettitt,Shuo Ma,Stephan Stilgenbauer,Paula Cramer,Maria Aiello,Dave Johnson,Langdon L. Miller,Daniel Li,Thomas Jahn,Roger Dansey,Michael Hallek,Susan O'Brien +26 more
TL;DR: The combination of idelalisib and rituximab, as compared with placebo and r ituximabs, significantly improved progression-free survival, response rate, and overall survival among patients with relapsed CLL who were less able to undergo chemotherapy.
Journal ArticleDOI
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang,Simon Rule,Peter Martin,Andre Goy,Rebecca Auer,Brad S. Kahl,Brad S. Kahl,Wojciech Jurczak,Ranjana H. Advani,Jorge E. Romaguera,Michael E. Williams,Jacqueline C. Barrientos,Ewa Chmielowska,John Radford,Stephan Stilgenbauer,Martin Dreyling,Wiesław Wiktor Jędrzejczak,Peter Johnson,Stephen E. Spurgeon,Lei Li,Liang Zhang,Kate J. Newberry,Zhishuo Ou,Nancy Cheng,Bingliang Fang,Jesse McGreivy,Fong Clow,Joseph J. Buggy,Betty Y. Chang,Darrin M. Beaupre,Lori Kunkel,Kristie A. Blum +31 more
TL;DR: Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma and is enrolled into two groups: patients who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles.
Journal ArticleDOI
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
John C. Byrd,Jennifer R. Brown,Susan O'Brien,Jacqueline C. Barrientos,Neil E. Kay,Nishitha Reddy,Steven Coutre,Constantine S. Tam,Stephen P. Mulligan,Ulrich Jaeger,S Devereux,Paul M. Barr,Richard R. Furman,Thomas J. Kipps,Florence Cymbalista,Christopher Pocock,Patrick Thornton,Federico Caligaris-Cappio,Tadeusz Robak,Julio Delgado,Stephen J. Schuster,Marco Montillo,Anna Schuh,S. de Vos,Devinder Gill,Adrian Bloor,Claire Dearden,Carol Moreno,Jeffrey Jones,Alvina D. Chu,Maria Fardis,Jesse McGreivy,Fong Clow,Danelle F. James,Peter Hillmen +34 more
TL;DR: Ibrutinib, as compared with ofatumumab, significantly improved progression-free survival, overall survival, and response rate among patients with previously treated CLL or SLL.
Journal ArticleDOI
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach,Richard R. Furman,Ta-Ming Liu,Hatice Gulcin Ozer,Marc Zapatka,Amy S. Ruppert,Ling Xue,Daniel Hsieh Hsin Li,Susanne M. Steggerda,Matthias Versele,Sandeep S. Dave,Jenny Zhang,Ayse Selen Yilmaz,Samantha Jaglowski,Kristie A. Blum,Arletta Lozanski,Gerard Lozanski,Danelle F. James,Jacqueline C. Barrientos,Peter Lichter,Stephan Stilgenbauer,Joseph J. Buggy,Betty Y. Chang,Amy J. Johnson,John C. Byrd +24 more
TL;DR: Functional analysis showed that the C481S mutation of BTK results in a protein that is only reversibly inhibited by ibrutinib, which underscores the importance of the B-cell-receptor pathway in the mechanism of action of ibrUTinib in CLL.
Journal ArticleDOI
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wyndham H. Wilson,Ryan M. Young,Roland Schmitz,Yandan Yang,Stefania Pittaluga,George E. Wright,Chih Jian Lih,P. Mickey Williams,Arthur L. Shaffer,John F. Gerecitano,John F. Gerecitano,Sven de Vos,Andre Goy,Vaishalee P. Kenkre,Paul M. Barr,Kristie A. Blum,Andrei R. Shustov,Ranjana H. Advani,Nathan Fowler,Julie M. Vose,Rebecca Elstrom,Thomas M. Habermann,Jacqueline C. Barrientos,Jesse McGreivy,Maria Fardis,Betty Y. Chang,Fong Clow,Brian Munneke,Davina Moussa,Darrin M. Beaupre,Louis M. Staudt +30 more
TL;DR: The selective development of ibrutinib for the treatment of ABC DLBCL is supported, with the highest number of responses occurred in ABC tumors that lacked BCR mutations, suggesting that oncogenic BCR signaling in ABC does not require B CR mutations and might be initiated by non-genetic mechanisms.